Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Yi Miao; Yeqin Sha; Yi Xia; Shuchao Qin; Rui Jiang; Luomengjia Dai; Hui Shen; Tonglu Qiu; Wei Wu; Jingyan Qiu; Yilian Yang; Chongyang Ding; Yujie Wu; Lei Fan; Wei Xu; Jianyong Li; Huayuan Zhu

doi:10.1038/s41408-023-00890-y

Ibrutinib plus fludarabine, cyclophosphamide and rituximab (iFCR) as initial treatment in chronic lymphocytic leukemia/ small lymphocytic leukemia with or without TP53 aberrations: a prospective real-world study in Chinese cohort

Blood Cancer J. 2023 Aug 9;13(1):121. doi: 10.1038/s41408-023-00890-y.

Authors

Yi Miao^#^{1

2

3}, Yeqin Sha^#^{1

2

3}, Yi Xia^#^{1

2

3}, Shuchao Qin^#^{1

2

3}, Rui Jiang^{1

2

3}, Luomengjia Dai^{1

2

3}, Hui Shen^{1

2

3}, Tonglu Qiu^{1

2

3}, Wei Wu^{1

2

3}, Jingyan Qiu², Yilian Yang², Chongyang Ding⁴, Yujie Wu^{1

2

3}, Lei Fan^{1

2

3}, Wei Xu^{5

6

7}, Jianyong Li^{8

9

10}, Huayuan Zhu^{11

12

13}

Affiliations

¹ Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
² Pukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China.
³ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 210029, Nanjing, Jiangsu, China.
⁴ Department of Nuclear Medicine, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China.
⁵ Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China. xuwei0484@jsph.org.cn.
⁶ Pukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China. xuwei0484@jsph.org.cn.
⁷ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 210029, Nanjing, Jiangsu, China. xuwei0484@jsph.org.cn.
⁸ Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China. lijianyonglm@126.com.
⁹ Pukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China. lijianyonglm@126.com.
¹⁰ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 210029, Nanjing, Jiangsu, China. lijianyonglm@126.com.
¹¹ Department of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, 210029, Nanjing, Jiangsu, China. huayuan.zhu@hotmail.com.
¹² Pukou Chronic Lymphocytic Leukemia (CLL) Center, Pukou division of Jiangsu Province Hospital, 211800, Nanjing, Jiangsu, China. huayuan.zhu@hotmail.com.
¹³ Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, 210029, Nanjing, Jiangsu, China. huayuan.zhu@hotmail.com.

^# Contributed equally.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Cyclophosphamide / therapeutic use
East Asian People
Humans
Leukemia, Lymphocytic, Chronic, B-Cell* / drug therapy
Leukemia, Lymphocytic, Chronic, B-Cell* / genetics
Prospective Studies
Rituximab / therapeutic use
Tumor Suppressor Protein p53 / genetics
Vidarabine / therapeutic use

Substances

Rituximab
ibrutinib
fludarabine
Cyclophosphamide
Vidarabine
TP53 protein, human
Tumor Suppressor Protein p53